GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NGM Biopharmaceuticals Inc (NAS:NGM) » Definitions » ROC (Joel Greenblatt) %

NGM Biopharmaceuticals (NGM Biopharmaceuticals) ROC (Joel Greenblatt) % : -1,597.79% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is NGM Biopharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. NGM Biopharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1,597.79%.

The historical rank and industry rank for NGM Biopharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

NGM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1728.12   Med: -419.15   Max: -17.69
Current: -1728.12

During the past 8 years, NGM Biopharmaceuticals's highest ROC (Joel Greenblatt) % was -17.69%. The lowest was -1728.12%. And the median was -419.15%.

NGM's ROC (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -338.25 vs NGM: -1728.12

NGM Biopharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -126.00% per year.


NGM Biopharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for NGM Biopharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NGM Biopharmaceuticals ROC (Joel Greenblatt) % Chart

NGM Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -227.54 -610.76 -842.78 -1,345.71 -1,718.73

NGM Biopharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,424.47 -1,993.41 -1,766.15 -1,491.34 -1,597.79

Competitive Comparison of NGM Biopharmaceuticals's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, NGM Biopharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGM Biopharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NGM Biopharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where NGM Biopharmaceuticals's ROC (Joel Greenblatt) % falls into.



NGM Biopharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 10.993) - (14.606 + 0.107 + 6.251)
=-9.971

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 12.201) - (13.642 + 0 + 6.439)
=-7.88

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of NGM Biopharmaceuticals for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-118.652/( ( (7.819 + max(-9.971, 0)) + (7.033 + max(-7.88, 0)) )/ 2 )
=-118.652/( ( 7.819 + 7.033 )/ 2 )
=-118.652/7.426
=-1,597.79 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NGM Biopharmaceuticals  (NAS:NGM) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


NGM Biopharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of NGM Biopharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


NGM Biopharmaceuticals (NGM Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
333 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.
Executives
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David V Goeddel director, 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Irene Perlich officer: Principal Accounting Officer C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jin-long Chen director, officer: Chief Scientific Officer 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Opportunity Iii Gp, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Iv-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David J Woodhouse director, officer: CEO and acting CFO 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080

NGM Biopharmaceuticals (NGM Biopharmaceuticals) Headlines

From GuruFocus

NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities

By Stock market mentor Stock market mentor 01-09-2023

NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022

By GuruFocusNews GuruFocusNews 07-03-2022

NGM Bio to Participate in Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-02-2022